These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 21219127)

  • 1. Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone: report of two cases from South America.
    Beltran BE; Castillo JJ; Salas R; Quiñones P; Morales D; Cotrina E; Miranda RN; Sotomayor EM
    Leuk Lymphoma; 2011 Jan; 52(1):153-6. PubMed ID: 21219127
    [No Abstract]   [Full Text] [Related]  

  • 2. Histologic transformation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
    Lee E; Kim TM; Lim Y; Jeon YK; Go H; Kim CW; Heo DS
    J Clin Oncol; 2013 Jul; 31(19):e332-4. PubMed ID: 23715578
    [No Abstract]   [Full Text] [Related]  

  • 3. Bilateral psoas muscle lymphoma: an unusual presentation of EBV-positive diffuse large B-cell lymphoma of the elderly.
    Ikebe T; Sasaki H; Saburi Y; Ogata M
    Int J Hematol; 2015 Nov; 102(5):509-10. PubMed ID: 26440976
    [No Abstract]   [Full Text] [Related]  

  • 4. Leukocytoclastic vasculitis as early manifestation of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly.
    Zoroquiain P; González S; Molgó M; Rodríguez A; Valbuena JR
    Am J Dermatopathol; 2012 May; 34(3):330-4. PubMed ID: 22197862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Fabbri A; Gozzetti A; Rigacci L
    Cancer; 2011 Aug; 117(15):3530; author reply 3531. PubMed ID: 21287541
    [No Abstract]   [Full Text] [Related]  

  • 6. Secondary cutaneous Epstein-Barr virus-associated diffuse large B-cell lymphoma in a patient with angioimmunoblastic T-cell lymphoma: a case report and review of literature.
    Yang QX; Pei XJ; Tian XY; Li Y; Li Z
    Diagn Pathol; 2012 Jan; 7():7. PubMed ID: 22260632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus (EBV) positive diffuse large B cell lymphoma of the elderly-experience of a single center from Turkey.
    Ozsan N; Cagirgan S; Saydam G; Gunes A; Hekimgil M
    Pathol Res Pract; 2013 Aug; 209(8):471-8. PubMed ID: 23726928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of reduced-dose 21-day cycle rituximab and cyclophosphamide, doxorubicin, vincristine and prednisolone therapy for elderly patients with diffuse large B-cell lymphoma.
    Aoki K; Takahashi T; Tabata S; Kurata M; Matsushita A; Nagai K; Ishikawa T
    Leuk Lymphoma; 2013 Nov; 54(11):2441-7. PubMed ID: 23452117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [EBV-positive diffuse large B-cell lymphoma in young individual: report of a case].
    Li WS; Xie JL; Zhang M; Zhou XG
    Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):128-9. PubMed ID: 23710923
    [No Abstract]   [Full Text] [Related]  

  • 11. Epstein-Barr virus-negative, CD5-positive diffuse large B-cell lymphoma developing after treatment with oral tacrolimus for mixed connective tissue disease : a case report and review of the literature.
    Sekiguchi Y; Shimada A; Imai H; Wakabayashi M; Sugimoto K; Nakamura N; Sawada T; Komatsu N; Noguchi M
    J Clin Exp Hematop; 2012; 52(3):211-8. PubMed ID: 23269082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
    Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
    Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-associated diffuse large B-cell lymphoma arising in atrial myxoma: a proposal for a modified therapeutic approach.
    Tapan U; Pestana JB; Lee JC; Lerner A
    Leuk Lymphoma; 2015 Feb; 56(2):505-7. PubMed ID: 24794809
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
    Sato A; Nakamura N; Kojima M; Ohmachi K; Carreras J; Kikuti YY; Numata H; Ohgiya D; Tazume K; Amaki J; Moriuchi M; Miyamoto M; Aoyama Y; Kawai H; Ichiki A; Hara R; Kawada H; Ogawa Y; Ando K
    Cancer Sci; 2014 Sep; 105(9):1170-5. PubMed ID: 24974976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synchronous Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly and Epstein-Barr virus-positive classical Hodgkin lymphoma.
    Hwang YY; Leung AY; Lau WH; Loong F; So JC; Tse E; Kwong YL
    Histopathology; 2011 Aug; 59(2):352-5. PubMed ID: 21884219
    [No Abstract]   [Full Text] [Related]  

  • 17. Intravascular large B cell lymphoma: widespread but not everywhere.
    Ponzoni M; Ferreri AJ
    Acta Haematol; 2014; 131(1):16-7. PubMed ID: 24021531
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma.
    Kasahara S; Hara T; Tsurumi H; Goto N; Kitagawa J; Kanemura N; Yoshikawa T; Goto H; Fukuno K; Yamada T; Sawada M; Takahashi T; Takami T; Moriwaki H
    Leuk Lymphoma; 2011 Apr; 52(4):629-34. PubMed ID: 21438831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple cytokine-producing aggressive EBV-positive diffuse large B cell lymphoma, not otherwise specified with hemophagocytic syndrome.
    Nakayama S; Morita Y; Espinoza JL; Rai S; Taniguchi Y; Taniguchi T; Miyake Y; Tanaka H; Ashida T; Matsumura I
    Ann Hematol; 2020 Feb; 99(2):381-383. PubMed ID: 31768673
    [No Abstract]   [Full Text] [Related]  

  • 20. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.